Prepartum Relapses or Treatment Resistance: A Case of Unipolar Mania

Because of treatment resistance and risks to be considered in the choice of treatment, peripartum psychotic and manic episodes constitute treatment challenges. For perinatal psychosis, there is also the consideration of a substantial subgroup showing the phenomenon of relapse, defined as the recurrence of symptoms after a brief period of symptom reduction. We report prepartum relapses of psychotic manic episodes in a 30-year-old female patient with a 15-year history of bipolar disorder. After 4-month medication-free period due to pregnancy, the patient, who had been in remission for 8 years with a combination of risperidone, valproic acid, and lithium, suffered multiple relapses that could not managed with electroconvulsive therapy and antipsychotic medication. Later, her symptoms only managed with lithium addition to her treatment. In this report, we discuss the treatment of bipolar disorder in pregnancy in the context of prepartum relapse and treatment resistance.

[1]  R. Baldessarini,et al.  Pharmacological treatment of adult bipolar disorder , 2019, Molecular Psychiatry.

[2]  M. Galbally,et al.  Mood stabilizers in pregnancy and child developmental outcomes: A systematic review , 2017, The Australian and New Zealand journal of psychiatry.

[3]  I. Brockington The Psychoses of Menstruation and Childbearing , 2017 .

[4]  I. Brockington,et al.  An international position paper on mother-infant (perinatal) mental health, with guidelines for clinical practice , 2016, Archives of Women's Mental Health.

[5]  Selçuk Özdin,et al.  Sociodemographic features and treatments of pregnant psychiatric inpatients in an university hospital: a retrospective chart review - , 2015 .

[6]  L. Brandt,et al.  Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study , 2012, BMJ : British Medical Journal.

[7]  T. Tomson,et al.  Teratogenic effects of antiepileptic drugs , 2012, The Lancet Neurology.

[8]  K. Fountoulakis Refractoriness in Bipolar Disorder: Definitions and Evidence‐Based Treatment , 2012, CNS neuroscience & therapeutics.

[9]  M. Loane,et al.  Valproic acid monotherapy in pregnancy and major congenital malformations. , 2010, The New England journal of medicine.

[10]  S. Gentile Antipsychotic therapy during early and late pregnancy. A systematic review. , 2010, Schizophrenia bulletin.

[11]  J. Calabrese,et al.  The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. , 2009, Bipolar disorders.

[12]  R. Baldessarini,et al.  Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. , 2007, The American journal of psychiatry.

[13]  John M. Davis,et al.  Defining ‘Response’ in Antipsychotic Drug Trials: Recommendations for the Use of Scale-Derived Cutoffs , 2007, Neuropsychopharmacology.

[14]  C. Perry,et al.  Spotlight on Lamotrigine in Bipolar Disorder , 2004, CNS Drugs.

[15]  C. Ernst,et al.  The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. , 2002, The Journal of clinical psychiatry.

[16]  J. Jefferson,et al.  A reevaluation of risk of in utero exposure to lithium. , 1994, JAMA.

[17]  S. Fekete,et al.  Use of Antipsychotics in the Management of Schizophrenia during Pregnancy , 2012, Drugs.

[18]  M. Brodie Valproic Acid Monotherapy in Pregnancy and Major Congenital Malformations , 2011 .

[19]  F. Karadağ,et al.  [Reliability and validity of Turkish translation of Young Mania Rating Scale]. , 2002, Turk psikiyatri dergisi = Turkish journal of psychiatry.